Trust Co. of Vermont decreased its position in Medtronic PLC (NYSE:MDT) by 9.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,913 shares of the medical technology company’s stock after selling 1,714 shares during the period. Trust Co. of Vermont’s holdings in Medtronic PLC were worth $1,282,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Sunbelt Securities Inc. acquired a new stake in shares of Medtronic PLC during the fourth quarter worth about $105,000. Intellectus Partners LLC acquired a new stake in shares of Medtronic PLC during the fourth quarter worth about $130,000. Baystate Wealth Management LLC raised its stake in shares of Medtronic PLC by 40.9% in the first quarter. Baystate Wealth Management LLC now owns 1,959 shares of the medical technology company’s stock worth $157,000 after buying an additional 569 shares during the last quarter. North Star Investment Management Corp. raised its stake in shares of Medtronic PLC by 4.4% in the first quarter. North Star Investment Management Corp. now owns 1,973 shares of the medical technology company’s stock worth $159,000 after buying an additional 83 shares during the last quarter. Finally, SRS Capital Advisors Inc. acquired a new stake in shares of Medtronic PLC during the fourth quarter worth about $141,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Shares of Medtronic PLC (NYSE:MDT) opened at 88.08 on Friday. The company’s 50 day moving average price is $84.84 and its 200 day moving average price is $79.22. Medtronic PLC has a one year low of $69.35 and a one year high of $89.27. The stock has a market capitalization of $120.58 billion, a P/E ratio of 30.48 and a beta of 1.04.

Medtronic PLC (NYSE:MDT) last announced its earnings results on Thursday, May 25th. The medical technology company reported $1.33 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.02. Medtronic PLC had a return on equity of 12.72% and a net margin of 13.56%. The firm had revenue of $7.92 billion during the quarter, compared to the consensus estimate of $7.86 billion. During the same quarter in the prior year, the company earned $1.27 EPS. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, equities analysts expect that Medtronic PLC will post $4.95 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/trust-co-of-vermont-sells-1714-shares-of-medtronic-plc-mdt/1371925.html.

MDT has been the topic of a number of research analyst reports. Needham & Company LLC raised their price target on Medtronic PLC from $84.00 to $91.00 and gave the stock a “buy” rating in a research note on Tuesday, February 21st. Wedbush reissued a “neutral” rating and issued a $85.00 price target on shares of Medtronic PLC in a research note on Wednesday, February 22nd. Evercore ISI raised their price target on Medtronic PLC from $78.00 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday, February 21st. Leerink Swann raised their price target on Medtronic PLC from $80.00 to $85.00 and gave the stock a “market perform” rating in a research note on Thursday, February 23rd. Finally, Morgan Stanley raised their price target on Medtronic PLC from $84.00 to $86.00 and gave the stock an “equal weight” rating in a research note on Tuesday, May 30th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $88.88.

In related news, EVP Hoedt Rob Ten sold 50,757 shares of the stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $81.58, for a total transaction of $4,140,756.06. Following the completion of the sale, the executive vice president now owns 59,392 shares in the company, valued at approximately $4,845,199.36. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.25% of the stock is owned by corporate insiders.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.